Bristol-Myers Squibb and Celldex Therapeutics, Inc. have entered into a clinical trial collaboration to evaluate BMS’ nivolumab, an investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study.   The trial will evaluate safety, tolerability and efficacy in multiple tumor types, potentially including non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC), and squamous cell head and neck cancers...